CN110893203A - Double-order nux vomica processed product extract and preparation method thereof - Google Patents
Double-order nux vomica processed product extract and preparation method thereof Download PDFInfo
- Publication number
- CN110893203A CN110893203A CN201911021646.7A CN201911021646A CN110893203A CN 110893203 A CN110893203 A CN 110893203A CN 201911021646 A CN201911021646 A CN 201911021646A CN 110893203 A CN110893203 A CN 110893203A
- Authority
- CN
- China
- Prior art keywords
- nux vomica
- strychnine
- processed product
- processed
- product extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The invention provides a double-order nux vomica processed product extract, wherein the active ingredients of the double-order nux vomica processed product extract are strychnine and alkaloid generated by the reaction of strychnine and phenolic or weakly acidic ingredients in ginger. The double-stage processed nux vomica product extract provided by the invention overcomes the defect that a small amount of strychnine and strychnine is remained in the nux vomica extract; the volume is reduced, and conditions are created for the formulation development of the processed products of nux vomica.
Description
Technical Field
The invention relates to a traditional Chinese medicine extract, in particular to a nux vomica concocted product extract.
Technical Field
Semen Strychni is dried mature seed of Strychni Pulveratum (S t r y h o n S nux-vomica L.) and semen Strychni (S.Wallichiana Steudex D.C.: S.p ieriana.). Contains alkaloid 2-5%, mainly strychnine and strychnine. Strychnos nux-vomica is bitter in taste, cold in nature and toxic. It enters liver and spleen meridians. Has effects in dispersing pathogen accumulation, relieving swelling, dredging meridians, and relieving pain; is used for treating rheumatism, numbness, paralysis, carbuncle, swelling and pain, and traumatic injury. In the records of Yi Xue Zhong Can xi Lu, nux vomica is superior to other herbs in that it can open meridians and collaterals and reach joints thoroughly. The clinical application of nux vomica is not declined for nearly a thousand years, which shows that the nux vomica has obvious curative effect and can be called 'Duyaqiang agent good for Jiechu'. But at the same time, because it is a toxic drug, the clinical application of the medicine is greatly limited.
The therapeutic dose of raw nux vomica is very close to the toxic dose, so the nux vomica needs to be processed firstly. The processing of Chinese herbs has been done by sand-scalding, frying, processing with licorice, soaking in vinegar, and burst-pressing, and the common purpose is to reduce toxicity. Modern multiple toxicological experimental studies prove that the various processing methods have exact attenuation function. Studies by chenchenchenille et al show that: the processing has certain influence on strychnine and strychnine content. The toxicity can be reduced by processing with vinegar, frying and processing with liquorice; the content of strychnine and strychnine in vinegar-soaked products is greatly reduced, the toxicity is reduced, but the titer can also be reduced. The sand scald product contains higher amount of strychnine and strychnine than the raw product. Ding's and the like process the raw nux vomica by using a popcorn machine, which proves that the content of strychnine is lower by a bursting method compared with a sand ironing method, thereby improving the clinical medication safety and curative effect of the processed nux vomica product. Chen Shi et al used 4 different herba Ephedrae preparata methods to process semen Strychni, determined the contents of strychnine and strychnine in different processed semen Strychni products, and conducted acute toxicity, analgesic effect and antiinflammatory effect research. The results show that: 4 kinds of Chinese ephedra processed nux vomica processed by different methods have lower toxicity than the unprocessed nux vomica and the sand-heated product prepared by the pharmacopeia method, and a large number of researches show that the toxicity of the processed nux vomica is reduced, compared with the unprocessed product, the safety of the processed nux vomica is improved, and the clinical application of the nux vomica is expanded. The research results show that the processing purposes of the nux vomica are to reduce toxicity and increase curative effect and application range, and the traditional processing method is low in cost, but the attenuation effect is not ideal, and the operation is complex and time-consuming, so that a novel processing method which has exact curative effect and can greatly reduce the toxicity is needed.
Semen Strychni contains alkaloid, loganin, Doudouchun glycoside, chlorogenic acid, palmitic acid, fatty oil, protein, and polysaccharide. Wherein the total alkaloid accounts for 2 to 5 percent and is the main component. Mainly stryehnine (stryehnine) accounting for about 50% of the total alkali content, and Brucine (Brucine) content accounting for 30% -40%. And small amount of alkaloids such as isostrychnine, isomannine, pseudostrychnine, strychnine oxynitride, loganin, nuxvomicin, colubulin, Nofadrogen, Icaritin, strychnine oxynitride, and 2-hydroxy-3-methoxy brucine. Wherein strychnine and strychnine are the main active ingredients and toxic ingredients, and are also the ingredients which are researched more at present. Literature studies suggest that strychnine and strychnine content is reduced and isostrychnine, isomannine, strychnine oxynitride and strychnine oxynitride content are increased after raw strychnos nux-vomica is subjected to sand-ironing, and it is inferred that strychnine and strychnine are probably converted. Therefore, modern new analysis technology is necessary to deeply research the change and migration of the chemical components of the nux vomica and the processed products thereof, and the material bases of different processing methods can be more comprehensively explained.
Modern pharmacological studies show that nux vomica has the effects of exciting the central nervous system, treating cardiovascular system, resisting inflammation, treating immune system, resisting tumor, relieving pain, relieving cough, eliminating phlegm, relieving asthma, inhibiting bacteria, resisting arrhythmia and the like. The therapeutic dose of nux vomica can improve the excitation process and the inhibition process of cerebral cortex. The toxic dose can make cerebral cortex generate various time phase states, and severe poisoning can cause convulsion of whole body muscle spasticity and gradually leads to death of respiratory muscle spasm contraction asphyxia. Reports have shown that both strychnine and strychnine in extremely large doses prevent the action of cholinesterase on acetylcholine. Nux vomica can also directly damage renal tubular epithelial cells, resulting in acute renal failure and uremia. The researches prove that the nux vomica has definite curative effect but strong toxicity, and the clinical application of the nux vomica is greatly limited, so that a new processing method needs to be developed to achieve the aims of reducing toxicity and improving efficacy.
The applicant and the research team thereof carry out deep research on the attenuation and synergism mechanism of the new nux vomica processing technology, and research results show that a new nux vomica processing technology with two stages is obtained, and a Chinese patent 'a two-stage nux vomica processing method (application number: 201811157918.1)' is applied in 2018, 9, and 30 days; the research aims at improving the chemical structures of strychnine and strychnine which are main active ingredients in nux vomica by a new processing technology so as to achieve the aims of reducing toxicity and improving efficacy. However, the processed nux vomica products still contain a small amount of strychnine and strychnine, and the traditional processed nux vomica decoction pieces also limit the formulation development and clinical application of nux vomica.
Disclosure of Invention
Aiming at the problems, the invention provides a preparation method of a double-order nux vomica processed product extract, which comprises the following steps:
1) weighing semen Strychni, rhizoma Zingiberis recens and semen Phaseoli Radiati according to weight ratio, adding water, and boiling with strong fire for 60 min;
2) taking out semen Strychni, oven drying at 80 deg.C, and scalding with sand to obtain processed semen Strychni;
3) processing semen Strychni, pulverizing, extracting with ethanol solution of pH5 under reflux to obtain extractive solution;
4) recovering ethanol from the extracting solution, adjusting the pH value to 2-3 by using hydrochloric acid, filtering, adjusting the pH value of the filtrate to 9-10 by using ammonia water, evaporating by using a water bath, and drying to constant weight to obtain the double-order nux vomica processed product extract.
In the step 1), the mass ratio of the nux vomica to the ginger to the mung bean to the water is 10:20:1: 150.
And 3) adding 50% ethanol solution with the pH of 5, which is 6 times of the amount of the nux vomica seeds, heating and refluxing for 3 times, extracting for 1 hour each time, and combining ethanol extracting solutions to obtain an extracting solution.
A processed product extract of nux vomica is the processed product extract of nux vomica prepared by any one of the methods.
The active ingredients of the processed product extract of nux vomica are strychnine and alkaloid generated by the reaction of strychnine and phenolic or weakly acidic ingredients in ginger.
The beneficial technical effects of the invention are as follows: 1. the double-stage processed nux vomica product extract provided by the invention overcomes the defect that a small amount of strychnine and strychnine is remained in the nux vomica extract;
2. the volume is reduced, and conditions are created for the formulation development of the processed products of nux vomica.
Drawings
FIG. 1 is a process diagram for establishing a quality loss method;
FIG. 2 is a diagram of the filtration of strychnine and strychnine with mass loss of mother nucleus;
FIG. 3 is a score plot before and after molding;
FIG. 4 shows front and rear opls-da diagrams of molding.
Detailed Description
Example 1 preparation of extracts of processed double-rank Strychnos nux-vomica
With the same amount of nux vomica (100g), the addition amount of ginger, the water addition amount, the ginger decoction time, the nux vomica decoction time and the drying temperature are taken as main investigation factors, detection is carried out according to optimized chromatographic conditions after preparation is finished, and the processing technology is evaluated by taking the contents of strychnine and strychnine as indexes, which are specifically shown in table 1. The optimized processing method finally comprises the following steps: 100g of nux vomica, 200g of ginger and 10g of mung bean are added, 1.5kg of water is added, the mixture is boiled for 60min with strong fire, the mixture is put into the nux vomica to be boiled for 1.5 hours, the mixture is dried in an oven at 80 ℃, and then sand-ironing is carried out to obtain the double-order processed nux vomica product. Adding 50% ethanol solution with pH of 5 and 6 times of semen Strychni, heating and reflux-extracting for 3 times, each time for 1h, mixing the ethanol extracts, filtering, recovering ethanol, adjusting pH to 2-3 with hydrochloric acid, filtering, adjusting pH to 9-10 with ammonia water, evaporating in water bath, and drying to constant weight to obtain the extract of processed product of nux vomica. As can be seen from the liquid phase overlay, brucine and lesioning were not detected in the processed extract of nux vomica.
Example 2 component detection of processed product extract of nux vomica
The method comprises the steps of respectively taking strychnine and strychnine as mother cores, constructing a chemical component database (total 120 compounds) of ginger, presuming the type of reaction between phenolic or weakly acidic components in the ginger and alkaloid, and analyzing TOF data of the processed double-order nux vomica product extract obtained in example 1 by utilizing the mass defect screening function of PeakView software, wherein the TOF data are shown in figures 1 and 2.
Through mass loss, 23 new compounds are identified by taking strychnine as a mother nucleus, and 17 new compounds are identified by taking strychnine as a mother nucleus, which are shown in tables 1 and 2.
TABLE 1 analysis results of novel Compounds
TABLE 2 analysis results of the novel Compounds
Example 3 Activity Studies of processed double-stage Strychnos nux-vomica extract
Continuously gavage the rat for 3d, collecting serum sample after the last administration, establishing a rat toe swelling model, modeling, collecting the serum sample 30min later, centrifuging at 12000r/min ultra high speed, and taking the upper layer serum and a-80 ℃ refrigerator for later use.
Substituting mass spectrum data of samples before and after new process modeling into SIMCA software, establishing an OPLS-DA mathematical model, screening biomarkers through S-PLOT and VIP values, and importing the biomarkers into an established metabolite database to screen differential components by taking the data result of the biomarkers as an index. The results are shown in FIGS. 3 and 4.
ICR mice were divided into 3 groups (blank group, 270mg of crude drug powder of processed product of nux vomica, 11.5mg of extract of processed product of nux vomica (equivalent to 270mg of crude drug of processed product of nux vomica), and each group had 6 mice, male and female. Gavage once a day (0.5ml), gavage for 3 days continuously, after 1h of last administration, exposing the right ear of each group of mice, dripping dimethylbenzene in the middle of the ears of the mice by using a pipette gun except for the normal group, stopping dripping for 5s, dripping dimethylbenzene on the front side and the back side for 30ul, and taking the left ear as a blank control. And (3) after 30min, dislocating the cervical vertebra, cutting off double ears by using surgical scissors, punching down ear pieces at symmetrical positions of left and right ears by using a puncher, weighing by using an electronic balance, recording the weight, and calculating the swelling degree and the swelling rate. The results are shown in Table 3.
TABLE 3 mouse ear swelling test
Claims (5)
1. A preparation method of a processed product extract of nux vomica is characterized by comprising the following steps: the method comprises the following steps:
1) weighing semen Strychni, rhizoma Zingiberis recens and semen Phaseoli Radiati according to weight ratio, adding water, and boiling with strong fire for 60 min;
2) taking out semen Strychni, oven drying at 80 deg.C, and scalding with sand to obtain processed semen Strychni;
3) processing semen Strychni, pulverizing, extracting with ethanol solution of pH5 under reflux to obtain extractive solution;
4) recovering ethanol from the extracting solution, adjusting the pH value to 2-3 by using hydrochloric acid, filtering, adjusting the pH value of the filtrate to 9-10 by using ammonia water, evaporating by using a water bath, and drying to constant weight to obtain the double-order nux vomica processed product extract.
2. The method for preparing the processed product extract of nux vomica as claimed in claim 1, wherein: in the step 1), the mass ratio of the nux vomica to the ginger to the mung bean to the water is 10:20:1: 150.
3. The method for preparing the processed product extract of nux vomica as claimed in claim 1, wherein: and 3) adding 50% ethanol solution with the pH of 5, which is 6 times of the amount of the nux vomica seeds, heating and refluxing for 3 times, extracting for 1 hour each time, and combining ethanol extracting solutions to obtain an extracting solution.
4. The processed product extract of nux vomica is characterized in that: an extract of the processed product of nux vomica prepared by the method of any one of claims 1 and 3.
5. The processed double-rank nux vomica extract according to claim 4, wherein: the active ingredients of the processed product extract of nux vomica are strychnine and alkaloid generated by the reaction of strychnine and phenolic or weakly acidic ingredients in ginger.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021646.7A CN110893203A (en) | 2019-10-25 | 2019-10-25 | Double-order nux vomica processed product extract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021646.7A CN110893203A (en) | 2019-10-25 | 2019-10-25 | Double-order nux vomica processed product extract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110893203A true CN110893203A (en) | 2020-03-20 |
Family
ID=69786339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911021646.7A Withdrawn CN110893203A (en) | 2019-10-25 | 2019-10-25 | Double-order nux vomica processed product extract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110893203A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116143796A (en) * | 2023-03-08 | 2023-05-23 | 西安交通大学 | Monoterpene indole alkaloid extracted and separated from nux vomica, and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106756A (en) * | 2018-09-30 | 2019-01-01 | 重庆市中药研究院 | A kind of double rank horse spleen ferrtin methods |
-
2019
- 2019-10-25 CN CN201911021646.7A patent/CN110893203A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106756A (en) * | 2018-09-30 | 2019-01-01 | 重庆市中药研究院 | A kind of double rank horse spleen ferrtin methods |
Non-Patent Citations (2)
| Title |
|---|
| 秦伟瀚: "基于植物代谢组学方法的马钱子油炸炮制前后化学差异研究", 《天然产物研究与开发》 * |
| 赵雪等: "配伍生姜对马钱子毒性影响的实验研究", 《山东中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116143796A (en) * | 2023-03-08 | 2023-05-23 | 西安交通大学 | Monoterpene indole alkaloid extracted and separated from nux vomica, and preparation method and application thereof |
| CN116143796B (en) * | 2023-03-08 | 2023-12-15 | 西安交通大学 | Monoterpene indole alkaloid extracted and separated from nux vomica, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105232961B (en) | A kind of concocting method of rhizoma polygonati | |
| CN103705594B (en) | Chinese medicine composition for the treatment of hyperlipemia and preparation method thereof | |
| CN114917272B (en) | Baking and processing technology of nux vomica | |
| CN101695520B (en) | Preparation method of medicament for treating diabetes | |
| CN110893203A (en) | Double-order nux vomica processed product extract and preparation method thereof | |
| CN102305839A (en) | Detection method of traditional Chinese medicine composition for freeing lung and relieving asthma | |
| CN102370695A (en) | Qinglongyi active extract, its preparation method and its application | |
| CN104257735A (en) | Method for preparing milkvetch root fried with honey | |
| CN103655791A (en) | Lotus leaf-based preparation for treating phlegm and blood stasis simultaneously and application thereof | |
| CN103055191B (en) | Preparation method and quality detection method of traditional Chinese medicine for treating hematuresis caused by nephritis | |
| CN102697932B (en) | Medicinal composition for treating skin itch and quality detection method | |
| CN105030855B (en) | A kind of prevention and cure of cardiovascular disease, hyperlipemia health protection tea and preparation method thereof and detection method | |
| CN111481647B (en) | Compound coptis composition and preparation process thereof | |
| CN103520298A (en) | Traditional Chinese medicine granules having effects of harmonizing liver and spleen, resisting inflammation and alleviating pains and preparation method thereof | |
| CN109106756A (en) | A kind of double rank horse spleen ferrtin methods | |
| CN107213176B (en) | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof | |
| CN113759007A (en) | Quality control method of curcuma kwangsiensis | |
| CN105168160B (en) | A kind of tablet of antelope's horn for common cold and preparation method thereof | |
| CN104815011A (en) | Mongolian medicine piper longum extract used for reducing blood fat | |
| CN1919273B (en) | Chinese medicinal composition for treating headache | |
| CN107823247A (en) | Application of the beans taro stem tuber ethanol extract in liver cell lipidosis is reduced | |
| CN103099856A (en) | White paeony root processed product and preparation method thereof | |
| CN101167861B (en) | Hypoglycemic compound traditional Chinese medicine liquid preparation and preparation method thereof | |
| AU2021100051A4 (en) | Antitumor formula and extraction method thereof | |
| CN115887598B (en) | Preparation method of compound preparation of channel warming soup |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200320 |
|
| WW01 | Invention patent application withdrawn after publication |